Home›The Library›DSIP
DSIP (Delta Sleep-Inducing Peptide)
No good reason to think it works as sold. Small human trials from the 1980s and 90s gave mixed, mostly weak results, and the largest controlled trial found the treatment "not likely to be of major therapeutic benefit." FDA's advisory committee reviewed it in 2026 for compounding eligibility and voted it down — the only one of seven reviewed peptides to be rejected.
In brief
Should you care? Yes — this is one of the few compounds here with real, old human trial data, and the largest of those trials, plus a 2026 regulatory review, both point the same modest-to-absent direction.The short version
- Real human trials exist from the 1980s-90s, with mixed and mostly weak results.
- The largest, most controlled trial found no major therapeutic benefit.
- Rejected by FDA's advisory committee in July 2026 — the only one of seven reviewed peptides voted down.
What it is
DSIP is a nonapeptide first isolated from rabbit brain in the 1970s, proposed to promote delta-wave (deep) sleep.
What the human trial evidence shows
Early small trials reported real short-term effects — one study of 7 severe-insomnia patients receiving 10 DSIP injections reported normalized sleep in 6 of them for 3 to 7 months afterward; another reported longer, higher-quality sleep with no daytime sedation. But a double-blind study of 16 chronic insomniacs found only weak objective improvements in sleep efficiency and latency, and concluded that short-term DSIP treatment was "not likely to be of major therapeutic benefit" — the largest and most controlled study in the group produced the most modest result, which is the pattern worth stating plainly rather than leading with the more dramatic early reports.
The 2026 regulatory verdict
At the same 23-24 July 2026 FDA Pharmacy Compounding Advisory Committee meeting that reviewed BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon, DSIP — referred to in some of that coverage as "emideltide" — was the only one of the seven rejected for Category 1/503A eligibility, voted down 6-7 with one abstention.
What this means
This is a case where the available old human data and a specific 2026 regulatory review point the same direction: a modest-to-absent reliable effect, and a real, recorded finding against it, not merely an absence of evidence.
References
- Early DSIP human trials, 1980s-90s (PubMed, multiple entries) — real, published papers; specific figures should be independently spot-checked before quoting exact numbers.
- FDA Pharmacy Compounding Advisory Committee, 23-24 July 2026 meeting; DSIP/emideltide rejected for Category 1/503A eligibility, voted down 6-7 with one abstention — the only one of seven reviewed peptides rejected, and the one where the committee agreed with FDA staff's own recommendation against it.